Your browser doesn't support javascript.
B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients.
Schrezenmeier, Eva; Rincon-Arevalo, Hector; Stefanski, Ana-Luisa; Potekhin, Alexander; Straub-Hohenbleicher, Henriette; Choi, Mira; Bachmann, Friederike; Pross, Vanessa; Hammett, Charlotte; Schrezenmeier, Hubert; Ludwig, Carolin; Jahrsdörfer, Bernd; Lino, Andreia; Eckardt, Kai-Uwe; Kotsch, Katja; Dörner, Thomas; Budde, Klemens; Sattler, Arne; Halleck, Fabian.
  • Schrezenmeier E; E Schrezenmeier, Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Rincon-Arevalo H; H Rincon-Arevalo, Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Stefanski AL; A Stefanski, Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Potekhin A; A Potekhin, MVZ Diaverum Neubrandenburg, Neubrandenburg, Germany.
  • Straub-Hohenbleicher H; H Staub-Hohenbleicher, Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Choi M; M Choi, Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Bachmann F; F Bachmann, Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Pross V; V Pross, Department for General and Visceral Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Hammett C; C Hammett, Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Schrezenmeier H; H Schrezenmeier, Institute of Transfusion Medicine, Ulm University, Ulm, Germany.
  • Ludwig C; C Ludwig, Institute of Transfusion Medicine, Ulm University, Ulm, Germany.
  • Jahrsdörfer B; B Jahrsdörfer, Institute of Transfusion Medicine, Ulm University, Ulm, Germany.
  • Lino A; A Lino, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.
  • Eckardt KU; K Eckardt, Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Kotsch K; K Kotsch, Department for General and Visceral Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Dörner T; T Döerner, Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Budde K; K Budde, Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Sattler A; A Sattler, Department for General and Visceral Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany arne.sattler@charite.de.
  • Halleck F; F Halleck, Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
J Am Soc Nephrol ; 2021 10 19.
Article in English | MEDLINE | ID: covidwho-1566580
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

Background:

Accumulating evidence suggests that solid organ transplant recipients, as opposed to the general population, show strongly impaired responsiveness towards standard SARS-CoV-2 mRNA-based vaccination, demanding alternative strategies for protection of this vulnerable group.

Methods:

In line with recent recommendations, a third dose of either heterologous ChAdOx1 (AstraZeneca) or homologous BNT162b2 (BioNTech) was administered to 25 kidney transplant recipients (KTR) without humoral response after 2 doses of BNT162b2, followed by analysis of serological responses and vaccine-specific B- and T-cell immunity.

Results:

9/25 (36%) KTR under standard immunosuppressive treatment seroconverted until day 27 after the third vaccination, while one patient developed severe COVID-19 infection immediately after vaccination. Cellular analysis seven days after the third dose showed significantly elevated frequencies of viral spike protein receptor binding domain specific B cells in humoral responders as compared to non-responders. Likewise, portions of spike-reactive CD4+ T helper cells were significantly elevated in seroconverting patients. Furthermore, overall frequencies of IL-2+, IL-4+ and polyfunctional CD4+ T cells significantly increased after the third dose, whereas memory/effector differentiation remained unaffected.

Conclusions:

Our data suggest that a fraction of transplant recipients benefits from triple vaccination, where seroconversion is associated with quantitative and qualitative changes of cellular immunity. At the same time, the study highlights that modified vaccination approaches for immunosuppressed patients still remain an urgent medical need.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Clinical Practice Guide / Qualitative research Language: English Journal subject: Nephrology Year: 2021 Document Type: Article Affiliation country: ASN.2021070966

Full text: Available Collection: International databases Database: MEDLINE Type of study: Clinical Practice Guide / Qualitative research Language: English Journal subject: Nephrology Year: 2021 Document Type: Article Affiliation country: ASN.2021070966